Screener
Beam Therapeutics BEAM Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Beam Therapeutics’s reported figures.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
FAQ
- What is Beam Therapeutics's free cash flow?
- Beam Therapeutics (BEAM) reported free cash flow of -$130.75M in Q1 2026.
- How has Beam Therapeutics's free cash flow changed year-over-year?
- Beam Therapeutics's free cash flow decreased by 22.2% year-over-year, from -$106.95M to -$130.75M.
- What is the long-term trend for Beam Therapeutics's free cash flow?
- Over 2 years (2021 to 2025), Beam Therapeutics's free cash flow has grown at a 78.4% compound annual growth rate (CAGR), from -$113.08M to -$360.05M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Beam Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude